Market for therapeutic proteins

The global market for therapeutic proteins was estimated to be $95.2 Bn in 2008 and is expected to grow to $160.1 Bn in 2013 (10-12% growth per annum). The largest market is the US, followed by Europe and Japan. Biogenerics are expected to create a multi-billion dollar market in the future as more and more of the patents on the first generation of protein therapeutics expire. The rising cost of existing and expensive protein drugs contrasts with the lower price and increasing availability of biosimilar medicines.

PolyTherics’ is ideally positioned to exploit the loss of patent protection on therapeutic proteins and the global pressure to reduce the cost of treatment by creating better versions of off-patent therapeutic proteins that can be manufacture economically.

Sources: Global Protein Therapeutic market analysis (Reportlinker, Sep 07); Protein Drugs: Global Markets and Manufacturing Technologies (bcc research, Oct 08)

“The application of novel approaches to PEGylation is beneficial for production. The PEGylation of disulphide bridges developed by Polytherics (Figure 6) is a technology which is likely to have application in the field of antibody fragments.”

Source: Liddell. Production Strategies for Antibody Fragment Therapeutics. BioPharm International, June 2, 2009